Innovate, expand global cooperation to promote growth

Adapting to the changing business environment and constantly renewing themselves are the solutions that SCIC-funded enterprises have implemented, thereby maintaining growth rates and achieving more success.

Ms. Han Thi Khanh Vinh, General Director of Vinapharm

Over the years, Vinapharm and its subsidiaries have actively cooperated with many partners in developed countries with the desire to increase the distribution of new, high-quality, highly effective products domestically, contributing to promoting the development of the Vietnamese pharmaceutical industry.

In the coming time, Vinapharm and enterprises with Vinapharm's capital contribution will continue to improve the quality of input factors; focus on investing in research and development; promote international cooperation, link with pharmaceutical corporations in developed countries to improve research capacity, increase technology and science content.

We propose to issue/amend regulations on investment incentives, accordingly, enterprises and investment projects in the pharmaceutical industry in the list of industries and professions with investment incentives will be entitled to special investment incentives and support policies, without being influenced by the scale of investment capital as at present; continue to improve the investment and business environment to encourage foreign investment in Vietnam in the field of pharmaceutical production...

Mr. Toshiyuki Ishii, member of the Board of Directors and CEO of Hau Giang Pharmaceutical

“Meet international standards and stay ahead of the trend”

In the context of globalization, Hau Giang Pharmaceutical Joint Stock Company (DHG Pharma) must continuously innovate and apply advanced technology to meet international standards and anticipate market trends. Investment in research and development (R&D), technology transfer and new product development are key factors helping DHG Pharma maintain its position as the leading pharmaceutical enterprise in Vietnam.

DHG Pharma has cooperated with Taisho (Japan) in technology transfer, exclusive product distribution, etc.; developing highly qualified human resources; improving production capacity, etc. These efforts help DHG Pharma maintain its leading position in the Vietnamese pharmaceutical industry and reach international standards. In particular, the support of SCIC will help DHG Pharma continue to develop sustainably, enhancing its position in the domestic and international pharmaceutical market.

Ms. Dao Thuy Ha, Member of Board of Directors, Deputy General Director of Traphaco

“Breakthrough and strong transformation”

After 2 years of restructuring with the orientation of "maintaining the No. 1 position in oriental medicine - investing in developing high-quality modern medicine", Traphaco has made a breakthrough and transformed strongly.

Becoming a shareholder of Traphaco in 2018, Daewoong and Traphaco have a strategic and comprehensive cooperation relationship in many fields, especially technology transfer. In addition, Traphaco invests heavily in quality control activities; research on first generic drugs...

During its operations, the Company has always received support and assistance from SCIC, through its capital representative directly participating in management, operations, and planning of medium and long-term development strategies.

Traphaco will continue to invest in research and development of high-quality oriental medicine and modern medicine, increase the number of new products, continue to deploy key medicinal herb growing areas according to GACP - WHO, actively transfer technology, create a breakthrough platform in drug production technology, promote revenue growth, expand market share...

Mr. Vu Anh Tuan, General Director of Bao Minh Joint Stock Corporation

“Flexible, proactive adaptation”

In 2024, Bao Minh will research and deploy new insurance products and promote risk assessment and control insurance compensation rates.

In the coming time, the Company will continue to strictly control business activities; promote the application of information technology; improve service quality, customer care; diversify products; expand the network...

Vietnam has deeply integrated, so the impact from the market on businesses is inevitable. To minimize the impact, businesses must be truly flexible and proactive in adapting.

By the end of September 2024, the total revenue of the entire Bao Minh system reached VND 5,418 billion, an increase of 10.31% over the same period in 2023. Bao Minh continues to maintain its position in the top 3 non-life insurance enterprises in the Vietnamese insurance market.

Source: https://baodautu.vn/doi-moi-mo-rong-hop-tac-toan-cau-de-thuc-day-tang-truong-d230094.html